INDICATIONS:
Credelio Quattro is indicated for the prevention of heartworm disease
caused by Dirofilaria immitis and for the
treatment and control of roundworm (immature adult and adult
Toxocara canis and adult
Toxascaris leonina), hookworm (fourth stage
larvae, immature adult, and adult
Ancylostoma caninum and adult
Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and
Echinococcus granulosus) infections.
Credelio Quattro kills adult fleas and is indicated for the treatment and
prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum
(lone star tick),
Dermacentor variabilis (American dog tick),
Ixodes scapularis (black-legged tick),
Rhipicephalus sanguineus (brown dog tick),
and Haemaphysalis longicornis (longhorned
tick)] for one month in dogs and puppies 8 weeks of age and older, and
weighing 3.3 pounds or greater. Credelio Quattro is indicated for the
prevention of
Borrelia burgdorferi infections (also known
as Lyme disease) as a direct result of killing
Ixodes scapularis vector ticks.
Credelio Quattro-CA1 is conditionally approved for the treatment of
infestations caused by New World screwworm (NWS;
Cochliomyia hominivorax) larvae (myiasis) in
dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or
greater.
Important Safety Information:
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs
to the isoxazoline class and has been associated with neurologic adverse
reactions like tremors, ataxia, and seizures even in dogs without a
history of seizures. Use with caution in dogs with a history of seizures
or neurologic disorders. Dogs should be tested for existing heartworm
infections before Credelio Quattro/Credelio Quattro-CA1 administration as
it is not effective against adult D.
immitis. The safe use in breeding, pregnant,
or lactating dogs has not been evaluated. The most frequently reported
adverse reactions in clinical trials were vomiting and diarrhea.
Credelio Quattro-CA1 is conditionally approved by the FDA pending a full
demonstration of effectiveness under application number 141-619. Treatment
of NWS myiasis includes removal of the larvae, lesion cleaning and
surgical debridement. Implement appropriate wound care and pain
management. For full prescribing information, see the Credelio
Quattro/Credelio Quattro-CA1
package insert.
Credelio Quattro, Elanco and the diagonal bar logo are trademarks of
Elanco or its affiliates.
© 2026 Elanco or its affiliates.